Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-359-9 | CAS number: 139-40-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17th March 1977
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Contains sufficient detail to suggest GLP-like characteristics even though no statement of certification is reported (reasonably thorough description of authors, dates, design, results, and interpretation).
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 977
- Report date:
- 1977
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: "apprisal of the safety of chemicals in foods, drugs and cosmetics (1959), the US Association of food and drug officials (AFDO).
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- other: Maurer, Th., Thomann, P., Weirich, E.G. and Hess, R. (1975) The optimization test in the guinea pig. A method for the predictive evaluation of the contact allergenicity of chemicals. Agents and Actions Vol. 5 (2), 174 - 179, 1975
- Deviations:
- not specified
- GLP compliance:
- no
- Type of study:
- Freund's complete adjuvant test
Test material
- Reference substance name:
- Propazine
- EC Number:
- 205-359-9
- EC Name:
- Propazine
- Cas Number:
- 139-40-2
- Molecular formula:
- C9H16ClN5
- IUPAC Name:
- 6-chloro-N2,N4-bis(propan-2-yl)-1,3,5-triazine-2,4-diamine
- Details on test material:
- Product designation: propazine
batch No. Lot. 368
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- other: Pirbright white strain
- Sex:
- male/female
- Details on test animals and environmental conditions:
- The test was performed on groups of 10 male and 10 female guinea pigs of the Pirbright white strain bred on our premises and weighing between 400 to 450 grams. The animals were housed individually in Macrolon cages, type. 3, kept at a constant room temperature of 22 ± 10 °C, at a relative humidity of 55 ± 5 % and on a 10 hours light cycle day. The animals received ad libitum standard guinea pig pellets NAFAG, No. 830, Gossau SG and water.
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal
- Vehicle:
- polyethylene glycol
- Concentration / amount:
- Both during the induction period and the challenge test has been used a solution of 0.1 % dilution of the test substance in polyethylene glycol (PEG 400) + saline (70 : 30 parts)
Challengeopen allclose all
- Route:
- intradermal and epicutaneous
- Vehicle:
- polyethylene glycol
- Concentration / amount:
- Both during the induction period and the challenge test has been used a solution of 0.1 % dilution of the test substance in polyethylene glycol (PEG 400) + saline (70 : 30 parts)
- No. of animals per dose:
- 20 animals
- Details on study design:
- During the induction period the animals received one injection every second day (except weekends) to a total of 10 intracutaneous injections of a freshly prepared 0.1 % dilution of G 30028 in polyethylene glycol (PEG 400) + saline (70 : 30 parts)
On the first day, injections of 0.1 ml were administered into the shaven skin of the right flank and the back, while on the following days a single intracutaneous injection was given into the back.
During the second and third week of the induction period the test material was .incorporated in a mixture of the normal vehicle with complete Bacto Adjuvant ( Bacto Adjuvant, complete Freud (difco, Michigan, USA) (vehicle : adjuvant = 1 : 1)
Fourteen days after the last sensitizing injection, a challenge injection of 0.1 ml of a freshly prepared 0.1 % dilution of the test substance in polyethylene glycol (PEG 400) + saline (70 : 30 parts) was administered into the skin of the left flank.
Twentyfour hours after each injection during the first week of the induction period and 24 hours after the challenge injection the reactions were recorded. Before examination, the reaction sites were depilated chemically (Butoquick®, 5 minutes). - Challenge controls:
- Fourteen days after the last sensitizing injection, a challenge injection of 0.1 ml of a freshly prepared 0.1 % dilution of the test substance in polyethylene glycol (PEG 400) + saline (70 : 30 parts) was administered into the skin of the left flank
- Positive control substance(s):
- no
Study design: in vivo (LLNA)
- Positive control substance(s):
- not specified
- Statistics:
- The two largest perpendicular diameters (in mm) and the increase in the skin fold thickness (in mm) were measured and by multiplication of these values reaction vo1ume was obtained (in id) for each reading from each animal. The mean volume plus one standard deviation of the induction reactions observed in the individual animal in the first week was taken as representing the skin irritation threshold for each animal. Any challenge reaction greater than this threshold value in the induction period was graded as an allergic reaction and the animal termed positive. The number of positive animals in the test group was compared with the number of animals in the control group (treated with the vehicle alone) that showed a nonspecific reaction of at least the same magnitude negative control (The exact Fisher test for comparison of the basic probability of two binominal distributions, L. Sachs, Statistische Auswertungsmethoden, Thieme Verlag, Stuttgart, 1971. A probability of less or equal to 0.01 was considered to indicate a significant difference).
Ten days after the intracutaneous challenge injection a subirritant dose of the test compound was applied epicutaneously under occlusive dressings which were left in place for 24 hours.
Results and discussion
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: control group
- No. with + reactions:
- 1
- Total no. in group:
- 20
- Clinical observations:
- see statistics
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: other: control group. No with. + reactions: 1.0. Total no. in groups: 20.0. Clinical observations: see statistics.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- No. with + reactions:
- 15
- Total no. in group:
- 20
- Clinical observations:
- see statistics
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. No with. + reactions: 15.0. Total no. in groups: 20.0. Clinical observations: see statistics.
- Reading:
- other: challenge reactions after occlusive epicutaneous administration of the test compound
- Hours after challenge:
- 24
- Group:
- test chemical
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Remarks on result:
- other: Reading: other: challenge reactions after occlusive epicutaneous administration of the test compound. . Hours after challenge: 24.0. Group: test group. No with. + reactions: 0.0. Total no. in groups: 20.0.
Any other information on results incl. tables
Under the experimental conditions employed, significant differences between the test group and the vehicle treated controls were only seen after intradermal challenge administration of. Test solution, i.e. when the skin barrier was intentionally bypassed.
No difference between the test and the control group was seen after epidermal challenge administration. The negative results upon epidermal challenge demonstrate that, in artificially sensitized guineapigs, exposure of the intact skin to the test compound does not provoke contact dermatitis.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
